OBJECTIVE: To establish an HPLC method for the assaying of silybin in Gantai capsule.
目的建立以高效液相色谱法测定肝泰胶囊中水飞蓟宾含量的方法。
The subject of the invention is to develop silybin glucoside solution with excellent coloring stability.
本发明的课题是开发着色稳定性优异的水飞蓟宾糖苷溶液。
The structure and fragmentation pathway of silybin were elucidated by electron spray ionization mass spectrometry (ESI-MS).
采用电喷雾离子阱(ESI - MS)质谱技术对水飞蓟宾的结构和裂解途径进行研究。
Methods Sustained-release silybin microspheres were prepared by the spherical crystallization technique with solid-dispersing and release-retarding polymers.
方法采用固体分散载体和阻滞性高分子材料，使用固体分散与球晶制粒相结合的技术制备水飞蓟宾缓释微球。
Methods: the optimum preparation condition were researched by orthogonal test according to the hardness of drop pills, appearance, smooth and the content of silybin.
方法：以滴丸的硬度、外观、表面光滑度、水飞蓟宾的含量为评价指标，采用正交试验法研究滴丸成型的最佳工艺条件。
The hepatoprotective potential of SPC was improved not only by the improvement of bioavailability of silybin according to complex silybin with PC, also by the synergic action of PC.
卵磷脂对水飞蓟宾的抗急性肝损伤具有协同作用，其不仅通过提高水飞蓟宾的生物利用度增强药效，而且其自身也具有保肝作用。
Results: SLC possesses the characteristics of the infrared spectrum of silybin and lecithin, its nuclear magnetic resonance spectrum showed that SLC was combined by non covalent bond.
结果：水飞蓟宾卵磷脂复合物具有水飞蓟宾和卵磷脂的红外光谱特征，其磷核磁共振波谱显示水飞蓟宾和卵磷脂间以非共价键结合。
The pharmacodynamic result shows that 7-site substituted dehydrogenized silybin ether can be expectantly used for preparing the medicament for preventing and treating the neurodegenerative diseases.
药效学结果表明该7位取代脱氢水飞蓟宾醚化合物可以预期用于制备防治神经退行性疾病类药物的用途。
The pharmacodynamic result shows that 7-site substituted dehydrogenized silybin ether can be expectantly used for preparing the medicament for preventing and treating the neurodegenerative diseases.
药效学结果表明该7位取代脱氢水飞蓟宾醚化合物可以预期用于制备防治神经退行性疾病类药物的用途。
应用推荐